Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Exosomes in Tumor
share announcement

Exosomes in Tumor

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (24 June 2024) | Viewed by 4549

Special Issue Editors

Dr. Sandra E. Ghayad

E-Mail Website
Guest Editor
Center for CardioVascular and Nutrition Research (C2VN), INSERM 1263, INRAE 1260, Aix-Marseille University, 13385 Marseille, France
Interests: exosomes; cancer; cardiovascular disease; paracrine signaling; biomarkers
Dr. Nader Hussein

E-Mail Website
Co-Guest Editor
Cancer Research Center, CRCL (Centre de Recherche en Cancérologie de Lyon), Lyon, France
Interests: exosomes; cancer; paracrine signaling; non-canonical proteins; biomarkers

Special Issue Information

Dear Colleagues,

Exosomes, small vesicles released by various cells, including cancer cells, carry a diverse cargo of proteins, lipids, and nucleic acids, which can be transferred to recipient cells, thereby influencing their behavior. They play a pivotal role in shaping the tumor microenvironment by contributing to promoting tumor–stroma crosstalk, angiogenesis, immune modulation, tumor-induced immune suppression, tumor growth, invasion, metastasis, and drug resistance.

Exosomes also hold immense diagnostic potential, serving as non-invasive biomarkers for cancer detection, prognosis, and treatment response assessment through liquid biopsies. Targeting exosomal cargo to inhibit tumor growth and modulate tumor-promoting signals shows potential for the development of novel anti-cancer strategies. Additionally, engineered exosomes offer a promising platform for targeted cancer therapy, delivering therapeutic agents to tumor cells while minimizing off-target effects and enhancing treatment efficacy.

This Special Issue of Cancers, titled "Exosomes in Tumors", welcomes original research articles and timely reviews on all aspects of exosomes to highlight the multifaceted roles of exosomes in tumor biology, their impact on tumor growth, invasion, metastasis, and drug resistance, as well as their diagnostic and therapeutic potentials that will open up new research avenues for precision oncology, offering opportunities for early detection and personalized treatment strategies in the fight against cancer.

Dr. Sandra E. Ghayad
Dr. Nader Hussein
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • exosomes
  • extracellular vesicles
  • cancer
  • tumors
  • paracrine signaling
  • molecular signature
  • biomarkers
  • drug resistance
  • therapeutic agents

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 3052 KiB  
Article
Exosome-Mediated Paracrine Signaling Unveils miR-1246 as a Driver of Aggressiveness in Fusion-Negative Rhabdomyosarcoma
by Farah Ramadan, Raya Saab, Farah Ghamloush, Rita Khoueiry, Zdenko Herceg, Ludovic Gomez, Bassam Badran, Philippe Clezardin, Nader Hussein, Pascale A. Cohen and Sandra E. Ghayad
Cancers 2024, 16(9), 1652; https://doi.org/10.3390/cancers16091652 - 25 Apr 2024
Cited by 1 | Viewed by 1904
Abstract
Rhabdomyosarcoma is a pediatric cancer associated with aggressiveness and a tendency to develop metastases. Fusion-negative rhabdomyosarcoma (FN-RMS) is the most commonly occurring subtype of RMS, where metastatic disease can hinder treatment success and decrease survival rates. RMS-derived exosomes were previously demonstrated to be [...] Read more.
Rhabdomyosarcoma is a pediatric cancer associated with aggressiveness and a tendency to develop metastases. Fusion-negative rhabdomyosarcoma (FN-RMS) is the most commonly occurring subtype of RMS, where metastatic disease can hinder treatment success and decrease survival rates. RMS-derived exosomes were previously demonstrated to be enriched with miRNAs, including miR-1246, possibly contributing to disease aggressiveness. We aimed to decipher the functional impact of exosomal miR-1246 on recipient cells and its role in promoting aggressiveness. Treatment of normal fibroblasts with FN-RMS-derived exosomes resulted in a significant uptake of miR-1246 paired with an increase in cell proliferation, migration, and invasion. In turn, delivery of miR-1246-mimic lipoplexes promoted fibroblast proliferation, migration, and invasion in a similar manner. Conversely, when silencing miR-1246 in FN-RMS cells, the resulting derived exosomes demonstrated reversed effects on recipient cells’ phenotype. Delivery of exosomal miR-1246 targets GSK3β and promotes β-catenin nuclear accumulation, suggesting a deregulation of the Wnt pathway, known to be important in tumor progression. Finally, a pilot clinical study highlighted, for the first time, the presence of high exosomal miR-1246 levels in RMS patients’ sera. Altogether, our results demonstrate that exosomal miR-1246 has the potential to alter the tumor microenvironment of FN-RMS cells, suggesting its potential role in promoting oncogenesis. Full article
(This article belongs to the Special Issue Exosomes in Tumor)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

19 pages, 4087 KiB  
Review
Exosomal DNA: Role in Reflecting Tumor Genetic Heterogeneity, Diagnosis, and Disease Monitoring
by Ziyi Xiang, Qihui Xie and Zili Yu
Cancers 2024, 16(1), 57; https://doi.org/10.3390/cancers16010057 - 21 Dec 2023
Cited by 2 | Viewed by 2159
Abstract
Extracellular vesicles (EVs), with exosomes at the forefront, are key in transferring cellular information and assorted biological materials, including nucleic acids. While exosomal RNA has been thoroughly examined, exploration into exosomal DNA (exoDNA)—which is stable and promising for cancer diagnostics—lags behind. This hybrid [...] Read more.
Extracellular vesicles (EVs), with exosomes at the forefront, are key in transferring cellular information and assorted biological materials, including nucleic acids. While exosomal RNA has been thoroughly examined, exploration into exosomal DNA (exoDNA)—which is stable and promising for cancer diagnostics—lags behind. This hybrid genetic material, combining contributions from both nuclear and mitochondrial DNA (mtDNA), is rooted in the cytoplasm. The enigmatic process concerning its cytoplasmic encapsulation continues to captivate researchers. Covering the entire genetic landscape, exoDNA encases significant oncogenic alterations in genes like TP53, ALK, and IDH1, which is vital for clinical assessment. This review delves into exosomal origins, the ins and outs of DNA encapsulation, and exoDNA’s link to tumor biology, underscoring its superiority to circulating tumor DNA in the biomarker arena for both detection and therapy. Amidst scientific progress, there are complexities in the comprehension and practical application of the exoDNA surface. Reflecting on these nuances, we chart the prospective research terrain and potential pitfalls, forging a path for future inquiry. By illuminating both the known and unknown facets of exoDNA, the objective of this review is to provide guidance to the field of liquid biopsy (LB) while minimizing the occurrence of avoidable blind spots and detours. Full article
(This article belongs to the Special Issue Exosomes in Tumor)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop